SML1954
X-34
≥90% (HPLC), powder, amyloid-specific fluorescent dye
別名:
1,4-Bis(3-carboxy-4-hydroxyphenylethenyl)benzene
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C24H18O6
CAS番号:
分子量:
402.40
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
製品名
X-34, ≥90% (HPLC)
Quality Level
assay
≥90% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2.0 mg/mL, clear
storage temp.
2-8°C
SMILES string
OC(C=C1)=C(C(O)=O)C=C1C=CC2=CC=C(C=CC3=CC=C(O)C(C(O)=O)=C3)C=C2
InChI
1S/C24H18O6/c25-21-11-9-17(13-19(21)23(27)28)7-5-15-1-2-16(4-3-15)6-8-18-10-12-22(26)20(14-18)24(29)30/h1-14,25-26H,(H,27,28)(H,29,30)
InChI key
MCBNOAYTZBUCSX-UHFFFAOYSA-N
関連するカテゴリー
Biochem/physiol Actions
Fluorescent, amyloid-specific dye
X-34 is a fluorescent, amyloid-specific dye. It binds at a different site than Pittsburgh Compound B and is a highly fluorescent marker for beta-sheet structures.
X-34 (1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-benzene) is one among the small-molecule γ-secretase modulators (GSMs) involved in lowering Aβ42 levels (the 42-residue isoform of the amyloid-β peptide). X-34 has also been used to visualize intracellular immunoreactive deposits with classic amyloid fibrillar ultrastructure in living transgenic Caenorhabditis elegans animals. It is also used as a histochemical stain for determining pathological changes in Alzheimer′s disease (AD).
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
SML1954-5MG: + SML1954-25MG: + SML1954-VAR: + SML1954-BULK:
jan
Marcus Bäck et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 22(51), 18335-18338 (2016-11-04)
Deposits comprised of amyloid-β (Aβ) are one of the pathological hallmarks of Alzheimer's disease (AD) and small hydrophobic ligands targeting these aggregated species are used clinically for the diagnosis of AD. Herein, we observed that anionic oligothiophenes efficiently displaced X-34
Andy P Tsai et al.
Neurobiology of disease, 153, 105303-105303 (2021-02-26)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, robust microgliosis, neuroinflammation, and neuronal loss. Genome-wide association studies recently highlighted a prominent role for microglia in late-onset AD (LOAD). Specifically, inositol polyphosphate-5-phosphatase (INPP5D), also known as SHIP1
Substrate-targeting ?-secretase modulators
Kukar TL
Nature, 453, 925-929 (2008)
Chantal M Ferguson et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(4), 2632-2652 (2024-02-20)
The most significant genetic risk factor for late-onset Alzheimer's disease (AD) is APOE4, with evidence for gain- and loss-of-function mechanisms. A clinical need remains for therapeutically relevant tools that potently modulate APOE expression. We optimized small interfering RNAs (di-siRNA, GalNAc)
Sangderk Lee et al.
Cell reports, 42(3), 112196-112196 (2023-03-06)
The E4 allele of Apolipoprotein E (APOE) is associated with both metabolic dysfunction and a heightened pro-inflammatory response: two findings that may be intrinsically linked through the concept of immunometabolism. Here, we combined bulk, single-cell, and spatial transcriptomics with cell-specific
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）